论文部分内容阅读
目的探讨吉西他滨联合顺铂治疗晚期非小细胞肺癌的临床疗效和毒性反应。方法经病理学证实的90例晚期非小细胞肺癌患者,采用吉西他滨1000mg/m2第1、8天和顺铂75mg/m2分3d给予,静脉滴注,21～28d为一个疗程,2个疗程后评价疗效。结果 90例患者均可进行临床评价,CR0例,PR37例,SD29例,PD24例。主要毒副作用为骨髓抑制,白细胞下降、血小板均下降,其次为胃肠道反应及肝肾功能异常,未见严重的过敏反应发生。结论吉西他滨联合顺铂是一种治疗晚期非小细胞肺癌安全有效的化疗方案。
Objective To investigate the clinical efficacy and toxicity of gemcitabine plus cisplatin in the treatment of advanced non-small cell lung cancer. Methods Ninety patients with advanced non-small cell lung cancer confirmed by pathology were treated with gemcitabine 1000 mg / m2 on day 1 and day 8 and cisplatin 75 mg / m2 on day 3 for intravenous drip for 21-28 days. After 2 courses of treatment, Evaluation of efficacy. Results All the 90 patients could be evaluated clinically. There were CR0 cases, PR37 cases, SD29 cases and PD24 cases. The main toxic and side effects of bone marrow suppression, leukopenia, platelets were decreased, followed by gastrointestinal reactions and liver and kidney dysfunction, no serious allergic reactions. Conclusion Gemcitabine combined with cisplatin is a safe and effective chemotherapy for advanced non-small cell lung cancer.